Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073528 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,286
- Enrollment target
NCT00073528 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,286 participants.
The verdict
NCT00073528, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,286 participants
- Enrollment target
Study Summary
This study evaluated and compared the efficacy and tolerability of lapatinib and letrozole, with letrozole and placebo in post-menopausal women with hormone receptor positive (ER positive and/or PgR positive) advanced or metastatic breast cancer, who had not received prior therapy for advanced or metastatic disease.
Interventions
- DRUG Placebo
- DRUG Letrozole
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,286 participants |
| Start Date | 2003-12-09 |
| Est. Completion | 2018-03-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073528
The ClinicalTrials.gov registry entry for NCT00073528 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,286 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00073528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073528 about?
NCT00073528 is a clinical study titled "Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer". This study evaluated and compared the efficacy and tolerability of lapatinib and letrozole, with letrozole and placebo in post-menopausal women with hormone receptor positive (ER positive and/or PgR positive) advanced or metastatic breast cancer, who had not received prior therapy for advanced or me...
What is the current status of trial NCT00073528?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,286 participants. The study started on 2003-12-09. Estimated completion is 2018-03-22.
What interventions are being tested in trial NCT00073528?
The interventions under investigation include: Placebo (DRUG), Letrozole (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT00073528?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.